Brandon Capital scores its biggest return ever with $2.1bn biotech acquisition
Brandon Capital led cancer therapeutics startup Myricx Bio’s $8.5m seed round in 2019. Now Novartis is buying it for up to $2.16 billion. One of Australia’s longest tenured VC firms will soon enjoy its best ever return on a single investment following Novartis’ US$1.1 billion ($1.58 billion) acquisition of London biotech startup Myricx Bio. Melbourne-headquartered […]